[Latest] Global Acute Respiratory Infection Market Size/Share Worth USD 20,796.6 Billion by 2033 at a 1.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
29 oct. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union
20 sept. 2024 08h10 HE
|
BioNTech SE
Der an Omikron KP.2 angepasste COVID-19-Impfstoff wird nach Zulassung durch die Europäische Kommission für Personen ab 6 Monaten verfügbar seinDaten zeigten, dass der an Omikron KP.2 angepasste...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
20 sept. 2024 08h10 HE
|
BioNTech SE
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron...
The National Civil Rights Museum Hosts Catalyst for Change Panel on Prostate Cancer Health Inequities in Black Men
10 sept. 2024 16h22 HE
|
National Civil Rights Museum
Memphis, TN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum (NCRM) is proud to present "Tackling Prostate Cancer Disparities in Black Men" as part of its Catalyst for Change...
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
09 sept. 2024 10h20 HE
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
22 août 2024 14h15 HE
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA...
Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
16 août 2024 06h45 HE
|
BioNTech SE
Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
16 août 2024 06h45 HE
|
BioNTech SE
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27 juin 2024 10h30 HE
|
BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
27 juin 2024 10h30 HE
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...